The released PHB2 binds to the nuclear and cytoplasmic ERα, and blocks E2-associated signaling pathways, thereby inhibiting the proliferation of ERα-positive breast cancer cells in vitro and in vivo. Here, ESR1 is linked to breast carcinoma.